Newsletter

Hello Traders,

Today’s play on AXXE has incredible profit potential! The company has been gaining overwhelming recognition from the investment community over the past few weeks and the trading volume on the stock has been on a steady rise.

Trading at $.55 AXXE could easily reach new potential highs as the hype starts to increase about this amazing company.

About AXXE - Axxess Pharma, Inc.

Axxess Pharma, Inc. is a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products in niche markets. Although they serve the General Practice market, Axxess Pharma, Inc. also distributes products that target Dermatology, Rheumatology, Gynecology, Urology and Nephrology markets.

Specializing in the marketing and distribution of both prescription and non-prescription medical products in niche markets, AXXE’s 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, high cholesterol, blood pressure, acute pain, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more.

With increased awareness we could see this Pharmaceutical Company go VIRAL.  Plus the company has been making impressive headlines lately including a Memorandum of Understanding (MOU) in which AXXE would receive world-wide exclusive rights, to market and sell a full line of pain relief and muscle recovery products, as well as develop and market a vitamin line under the TapouT brand.

Read Full Release Here:  http://finance.yahoo.com/news/axxess-pharma-inc-announces-mou-232000627.html

Mixed Martial Arts (MMA) is one of the fastest growing and most watched sports in this world!

In just a dozen years, UFC has grown into an enterprise valued at $2 billion, rivaling the market worth of the NFL’s Dallas Cowboys or Major League Baseball’s New York Yankees. 

UFC content is already broadcast by more than 30 TV networks in 28 languages in 145 nations with a potential of more than 800 million viewing households!

UFC’s annual revenues are more than $500 million!

Nick Woodhouse, President for TapouT/Authentic Brands Group stated, "We feel that Axxess incredible pain relief formulas are going to be well received by TapouT customers across North Amerca. As the TapouT brand continues to grow, Axxess will have an opportunity to grow with us." 

This NEW Relationship with TapouT could drive in Substantial Revenue for AXXE!

In addition to this AXXE just released even more news yesterday after the close!  

“Axxess Pharma Inc. Acquires Existing Revenues, Patents, Formulations and NFL, NHL, UFC Athlete Endorsed Products From Leading Canadian OTC Healthcare Company”

Axxess Pharma Inc. (OTCPK: AXXE), a specialty pharmaceutical and nutritional supplements company, today announced it has signed an Agreement for its acquisition of the assets of Revive Bioscience Inc. a leading Canadian OTC healthcare company, the terms of the deal remain private.

Revive Bioscience Inc.'s assets include revenues, product inventory, established sales channels, an attractive IP portfolio; including a best-selling, OTC pain relief formula and a number of other proprietary formulas.

Revive has a national distribution of products in Canada, through GNC and independent retail stores, and expects to add other large retail outlets later this year. The products Revive developed will be sold in mass retail stores across Canada (currently in market), USA and Mexico.

Further, the company has an exclusive world-wide license with one of the top sporting brands in the world. This license provides access to a global distribution network, including 20,000+ retailers. The branded products are endorsed by current athletes from the NFL, NHL and UFC.

Full Release Here: http://finance.yahoo.com/news/axxess-pharma-inc-acquires-existing-211516493.html

This is just two of of 8 exciting press releases that AXXE has issued over the past couple of months. With All this Great News from AXXE, it is No Wonder that Trading Volume has been so Significant in the past month.

Read all the recent news here at the company’s website: http://www.axxesspharmainc.com/news-press-releases.php

Market Outlook

The over-the-counter (OTC) pharmaceutical market includes non- prescription medicines that are sold directly to consumers through pharmacies, drugstores, convenience stores and grocery stores. Most countries follow the “two-class system” for the classification of medicines as prescription (Rx) or non-prescription (OTC). The OTC pharmaceutical market may be segmented into multiple categories such as analgesics, cold, cough and allergy, digestive remedies, traditional medicines, and vitamins and minerals.

A new report by visiongain predicts that the world market for over-the-counter (OTC) medicines will reach $80.7 billion for 2014. That revenue forecast appears in World OTC Pharmaceutical Market 2012-2022, published in June 2012.

Fortunately for us, AXXE closed yesterday near it’s 52-week low.

At the Price-Level, AXXE's Upside Potential appears to heavily outweigh Downside Risk!

Review AXXE's 6-Month Chart (Below) and you'll likely Understand Exactly what we mean.

AXXE has all the makings for a potential winner.  Start your research immediately and keep an eye on your inbox for more updates on today’s alert.

***Please sign up for my FREE Text Message list***

Emails tend to take too long to be received and my alerts immediately start gaining momentum when the market opens.  By signing up to my text messages you will receive my alerts at 9:30am EST every time!

Just text the words “StockAlerts” to “96362” and start
Receiving alerts immediately on your phone.

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

The disclaimer is to be read and fully understood before using our site, or joining our email list.

PLEASE NOTE WELL:  This report is for information purposes only, and is neither a solicitation nor recommendation to buy nor an offer to sell securities.  RisingPennyStocks and its employees are not a registered investment advisor and is not a broker-dealer in any jurisdiction whatsoever. Full disclaimer can be read at http://www.risingpennystocks.com/disclaimer

Release of Liability:
Through use of this website viewing or using you agree to hold RisingPennyStocks, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. RisingPennyStocks's affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any information, opinions and analysis contained herein are based upon sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  The opinions contained herein reflect our current judgment and are subject to change without notice. RisingPennyStocks accepts no liability for any losses arising from an investor’s reliance on the use of this material.  RisingPennyStocks has agreed to be compensated thirty thousand dollars for a one day public awareness marketing campaign for AXXE from the third party StockMister LLC. Consequently, RisingPennyStocks has an inherent conflict of interest in publishing this report. Upon receipt of the AXXE shares, the third party and/or their related persons and affiliated entities will sell shares of common stock of AXXE in the open market at any time without notice.  In some instances the third party identified herein has bought and sold, is buying and selling and will buy and sell shares of the featured company’s shares.  RisingPennyStocks will not update any purchases and sales of any shares of the company profiled in any future postings on RisingPennyStocks emails, website or other medium utilized to feature or disseminate information. Your purchase of AXXE shares will likely increase the value of your position in AXXE shares.  RisingPennyStocks and/or the third party, its related persons and affiliated entities, and sales by AXXE will likely decrease the value of your position in AXXE shares. RisingPennyStocks does not set price targets on securities.  All information on featured companies is provided by the companies profiled, or is available from public sources and RisingPennyStocks makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Any claims or Statements should be deemed apocryphal. RisingPennyStocks encourages readers and investors to supplement the information in these reports with independent research and other pro advice.